The CSL Limited (ASX: CSL) share price leapt 7% in November, and December looks like it could bring more joy. Experts are generally bullish on the Aussie biotechnology giant.

Particularly on the back of the company’s Hemgenix treatment, which recently received US Food and Drug Administration (FDA) approval. The gene therapy is designed to treat hemophilia B.

It has also reportedly been crowned the world’s most expensive treatment. A single dose is said to command a US$3.5 million price tag.

Right now, the CSL share price is $299.72.

Let’s take a look at what brokers are saying about the S&P/ASX 200 Index (ASX: XJO) healthcare giant.

What might the future hold for the CSL share price?

CSL appears to be a favourite among brokers and experts right now, with some predicting its share price to leap as high as $343.

That’s the prediction put forward by Macquarie, as my Fool colleague James reports. The top broker has a buy rating on the stock and expects Hemgenix’s early 2023 launch to boost the company’s earnings.

Citi is also hopeful for CSL, slapping the share with a buy rating and a $340 price target.

Not all brokers are so enthusiastic, however. Goldman Sachs’ most recent forecast, from early November, tips the CSL share price to fall to $291.

It’s worth noting that experts apparently aren’t tipping the company’s bottom line to be immediately buoyed by Hemgenix’s launch. Indeed, CSL chief commercial officer Bill Campbell recently told investors “it will take a little bit of time for questions to be answered in the commercial space”, the Australian Financial Review reports.

Looking beyond CSL and to the healthcare sector more broadly, Janus Henderson portfolio manager Andy Acker recently wrote, per Livewire:

[E]ven if major economies enter a recession in 2023, we believe the healthcare sector could offer investors some safe harbour. In the past, the sector has outperformed in the months leading up to and during economic downturns; the same could hold true again.

Additionally, Morgans equity analyst Anna Milne is said to like the prospects of the company’s Seqirus vaccine in the upcoming flu season and its recently-acquired Vifor iron deficiency therapy business. Morgans expects the CSL share price to lift to $327, according to Livewire.

All in all, many experts appear to believe December could be a good time to buy CSL stock ahead of an expected share price surge.

The post Is the CSL share price set to take off in December? appeared first on The Motley Fool Australia.

(function() {
function setButtonColorDefaults(param, property, defaultValue) {
if( !param || !param.includes(‘#’)) {
var button = document.getElementsByClassName(“pitch-snippet”)[0].getElementsByClassName(“pitch-button”)[0];
button.style[property] = defaultValue;
}
}

setButtonColorDefaults(“#0095C8”, ‘background’, ‘#5FA85D’);
setButtonColorDefaults(“#0095C8”, ‘border-color’, ‘#43A24A’);
setButtonColorDefaults(“#fff”, ‘color’, ‘#fff’);
})()

More reading

• Why CSL shares are this fundie’s top ASX 200 healthcare pick
• Why did the CSL share price leap 7% in November?
• ‘Buy it for 5 years’: Jun Bei Liu’s 3 best ASX shares for 2023
• ‘Back a winner’: Expert names his 3 best ASX shares for 2023
• 2 high quality blue chip ASX 200 shares named as buys by analysts

Citigroup is an advertising partner of The Ascent, a Motley Fool company. Motley Fool contributor Brooke Cooper has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended CSL. The Motley Fool Australia has recommended Macquarie Group. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

from The Motley Fool Australia https://ift.tt/Zz7nuYh

• Stock Market